Changeflow GovPing Pharma & Drug Safety EPO Patent Publication EP2026028952A1: Syntheti...
Routine Notice Added Final

EPO Patent Publication EP2026028952A1: Synthetic Protein and Related Compositions

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Biotech (C12N)
Published March 18th, 2026
Detected March 24th, 2026
Email

Summary

The European Patent Office has published patent application EP2026028952A1 concerning synthetic proteins, complexes, compositions, polynucleotides, expression vectors, and pharmaceutical compositions. The publication date is March 18, 2026, and it covers various applications including osteogenesis, cartilage proliferation, and angiogenesis promotion.

What changed

The European Patent Office (EPO) has published patent application EP2026028952A1, detailing inventions related to synthetic proteins, complexes, compositions, polynucleotides, expression vectors, transformants, and pharmaceutical compositions. The application, published on March 18, 2026, includes classifications for protein chemistry, pharmaceutical preparations, and molecular biology techniques.

This publication represents a new patent filing and does not impose immediate compliance obligations on regulated entities. However, it is relevant for companies operating in the biotechnology and pharmaceutical sectors involved in research, development, and intellectual property management. Companies should monitor the progress of this patent application and similar filings for potential impacts on their product development and market strategies.

Source document (simplified)

← EPO Patent Bulletin

SYNTHETIC PROTEIN, COMPLEX, COMPOSITION, POLYNUCLEOTIDE, EXPRESSION VECTOR, TRANSFORMANT, OSTEOGENESIS PROMOTER, CARTILAGE PROLIFERATION PROMOTER, ANGIOGENESIS PROMOTER, AND PHARMACEUTICAL COMPOSITION

Publication EP2026028952A1 Kind: A1 Mar 18, 2026

Inventors

The designation of the inventor has not yet been filed

IPC Classifications

C07K 19/00 20060101AFI20260207BHEP A61K 38/16 20060101ALI20260207BHEP A61K 38/22 20060101ALI20260207BHEP A61K 38/39 20060101ALI20260207BHEP A61P 9/00 20060101ALI20260207BHEP A61P 19/00 20060101ALI20260207BHEP A61P 19/08 20060101ALI20260207BHEP C07K 14/78 20060101ALI20260207BHEP C12N 1/15 20060101ALI20260207BHEP C12N 1/19 20060101ALI20260207BHEP C12N 1/21 20060101ALI20260207BHEP C12N 5/10 20060101ALI20260207BHEP C12N 15/62 20060101ALI20260207BHEP C07K 14/33 20060101ALI20260207BHEP C07K 14/575 20060101ALI20260207BHEP C12N 15/16 20060101ALI20260207BHEP C12N 15/31 20060101ALI20260207BHEP C12N 15/63 20060101ALI20260207BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

SYNTHETIC PROTEIN, COMPLEX, COMPOSITION, POLYNUCLEOTIDE, EXPRESSION VECTOR, TRANSFORMANT, OSTEOGENESIS PROMOTER, CARTILAGE PROLIFERATION PROMOTER, ANGIOGENESIS PROMOTER, AND PHARMACEUTICAL COMPOSITION

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 18th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP2026028952A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Drug Labeling Pharmaceutical Development
Geographic scope
European Union EU

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Compliance frameworks
FDA 21 CFR Part 11 GxP
Topics
Biotechnology Intellectual Property

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.